Human Longevity, Inc.

SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Human Longevity, Inc. today announced the creation of a new company, Human Life Foundation Models, Inc. (HLFM), dedicated to developing large-scale foundation models for human longevity science. HLFM's first strategic collaboration is with Insilico Medicine under a multi-year and multi-million dollar collaboration framework to address the rapidly emerging global longevity market, which UBS estimates will grow from approximately $5.3 trillion to nearly $8 trillion by 2030. Continue Reading Human Longevity’s Launched New Entity Human Life Foundation Models, Inc. and Insilico Medicine Collaborates to Build the First Foundation Model for Longevity Science HLFM will combine Human Longevity's unique de-identified multi-omic and clinical datasets with Insilico Medicine's cutting-edge artificial intelligence technologies. The goal of HLFM is to build one of the world's most comprehensive AI foundation models capable of predicting disease risk, understanding aging biology, and accelerating the development of preventive and therapeutic interventions to extend healthy human lifespan. Human Longevity has spent more than a decade building one of the world's largest integrated datasets of genomics, imaging, clinical, and longitudinal health information from thousands of individuals. HLFM's access to Human Longevity's reasoning data for health risk screening will be used to support its foundation models cognitive training process of detecting, diagnosing, and managing patient conditions. Insilico Medicine is globally recognized for its leadership in generative AI and deep learning systems for biology and drug discovery. Together, the companies aim to create a next-generation foundation model longevity platforms that can decode the biological mechanisms of aging and enable predictive healthcare shifting medicine from treating disease to preventing it. The collaboration is designed around a privacy preserving AI architecture in which raw patient-level data remains with its original owners and custodians and is not transferred, centralized, or shared across institutions or countries. Insilico Medicine will not have direct access to identifiable personal health data. Instead, Human Life Foundation Models will coordinate the development and training of next-generation biomedical world models within secure decentralized environments, while Insilico contributes advanced AI architecture, benchmark systems, and model teacher infrastructure. The goal is to enable predictive health insights at global scale while respecting local regulatory, ethical, and data sovereignty requirements. "Human Longevity was founded with the vision that large-scale biological data combined with artificial intelligence would fundamentally transform medicine," said Wei-Wu He, Executive Chairman of Human Longevity. "By having HLFM partnering with Insilico Medicine to build the human life foundation models, we are taking a major step toward creating a true foundation model for human health and longevity—one that can help predict complex disease decades before it occurs and guide interventions to extend healthy lifespan." "By combining Insilico's leadership in generative AI drug discovery and multimodal foundation models with one of the world's largest longitudinal human health datasets, we aim to build a next-generation AI system capable of decoding the biology of aging," said Alex Zhavoronkov, Founder, CEO and CBO of Insilico Medicine. "Human longevity and healthspan represent one of the most complex challenges in biology. This collaboration is about creating a true foundation model for human health that can identify disease risks earlier, uncover novel therapeutic targets, and accelerate the discovery of longevity therapeutics with unprecedented precision." HLFM will focus on building large multimodal AI models trained on genomic, proteomic, imaging, clinical, and longitudinal health data. These models are expected to enable breakthroughs in: Early detection of age-related diseases Predictive health risk modeling AI-driven longevity therapeutics discovery Personalized interventions to extend healthy lifespan The companies believe the convergence of large-scale biological datasets and generative AI technologies will help unlock significant opportunities across preventive healthcare, therapeutics discovery, diagnostics, and personalized longevity interventions within the multi-trillion-dollar global longevity market. The collaboration represents a long-term strategic commitment by both organizations to build foundational AI infrastructure for the emerging longevity economy. About Human Longevity, Inc: Founded in 2013, Human Longevity, Inc. is a biotechnology company at the forefront of integrating genomics, artificial intelligence, and multimodal diagnostics to extend human healthspan. Through its flagship Genomics Program, Executive Health Program and 100+ Longevity Programs, HLI delivers comprehensive, data-driven evaluations designed to identify and help prevent disease long before symptoms arise. Human Longevity is committed to extending healthy lifespan through proactive diagnostics and personalized preventive care, empowering individuals to stay ahead of disease. To learn more, visit . About Human Life Foundation Models (HLFM): HLFM is focused on developing multimodal AI foundation models for human health and longevity by integrating large-scale biological, clinical, imaging, and longitudinal health data with advanced artificial intelligence systems. About Insilico Medicine: Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit Media Contact: [email protected] [email protected] SOURCE Human Longevity, Inc. 21% more press release views with Request a Demo

Cambridge, Mass., May 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and Human Life Foundation Models, Inc. (HLFM), a newly launched company established by Human Longevity, Inc. today announced a multi-million-dollar AI co-development collaboration to build industry's first large-scale foundation models dedicated to human longevity science. As aging populations reshape global labor markets and consumer demand, longevity has transcended its origins as a niche scientific pursuit to become a major economic pillar. According to recent analysis by UBS, the global longevity market is currently valued at approximately $5.3 trillion and is on a trajectory to reach $8 trillion by 2030. Propelling this evolution is AI-driven drug discovery, which has emerged as a cornerstone of aging research by modeling aging biology, predicting disease risk, and accelerating the discovery of preventive and therapeutic interventions to extend healthy human lifespan. The collaboration between Insilico and HLFM aims to jointly develop a super-intelligence AI foundation model to decode the biological mechanisms of aging and enable predictive healthcare. Within this framework, Insilico will leverage its expertise in multimodal foundation model development and deep learning system engineering, building on the advanced training and evaluation capabilities of MMAI Gym to systematically deliver model architecture, benchmarking, training guidelines, and computational algorithms, providing the technical foundation for the jointly developed model. Human Life Foundation Models will integrate these tools and capabilities with Human Longevity's unique, de-identified multi-omic and clinical datasets to build advanced multimodal AI models. Drawing from over a decade of research, Human Longevity has curated one of the world's most comprehensive integrated datasets, spanning multi-omics, imaging, and longitudinal health records from thousands of individuals. By leveraging this vast repository, HLFM will support the foundation models' cognitive training, enabling the system to detect, diagnose, and manage patient conditions with clinical-grade precision. By fusing these advanced algorithms with deep biological insights, the jointly developed foundation models are expected to be commercially available to drive breakthroughs in the early detection of age-related diseases, predictive health risk modeling, and the discovery of novel AI-driven therapeutics and personalized interventions to extend healthy human lifespan. The companies believe that these advancements will play a pivotal role in the future of medicine by shifting the global healthcare paradigm from reactive disease treatment toward proactive and preventive longevity science. "By combining Insilico's expertise in generative AI drug discovery and multimodal foundation models with HLFM's unique datasets, and conducting rigorous model training and benchmark evaluation under the advanced MMAI Gym framework, we aim to build a next-generation AI system capable of decoding the biology of aging," said Alex Zhavoronkov, Founder, CEO and CBO of Insilico Medicine. "Human longevity and healthspan represent one of the most complex challenges in biology. This collaboration is about creating a true foundation model for human health that can identify disease risks earlier, uncover novel therapeutic targets, and accelerate the discovery of longevity therapeutics with unprecedented precision." "Human Longevity was founded with the vision that large-scale biological data combined with artificial intelligence would fundamentally transform medicine," said Wei-Wu He, Executive Chairman of Human Longevity. "By having HLFM partnering with Insilico Medicine to build the human life foundation models, we are taking a major step toward creating a true foundation model for human health and longevity—one that can help predict complex disease decades before it occurs and guide interventions to extend healthy lifespan." Longevity has been central to Insilico's mission since its inception. The company's journey gained industry notice in 2015 at the NVIDIA GTC conference, where Alex Zhavoronkov, PhD, founder and CEO of Insilico, challenged the tech world with a provocative question: "Can NVIDIA cure aging?". Recently, Insilico announced the industry's first longevity board composed of high-profile scientists and chaired by Andrew Adams, PhD, Group Vice President of Molecular Discovery at Eli Lilly and Company to accelerate AI-Driven aging research for drug discovery. Insilico has published over 50 research papers related to aging and longevity research, biomarkers of aging, therapeutic targets and therapeutics implicated in aging, longevity and disease since 2014. About Insilico Medicine Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit About Human Life Foundation Models (HLFM) Human Life Foundation Models, Inc. (HLFM) is focused on developing multimodal AI foundation models for human health and longevity by integrating large-scale biological, clinical, imaging, and longitudinal health data with advanced artificial intelligence systems. About Human Longevity, Inc. Founded in 2013, Human Longevity, Inc. integrates genomics, artificial intelligence, and multimodal diagnostics to extend human healthspan through proactive diagnostics and personalized preventive care. To learn more, visit Human Longevity. SOURCE Insilico Medicine 21% more press release views with Request a Demo

SOUTH SAN FRANCISCO, Calif., May 11, 2026 /PRNewswire/ -- Human Longevity, Inc. today announced the launch of its new Clinical-Grade $599 Whole Genome Sequencing Report, designed to bring advanced genomic medicine and AI-driven disease prevention to the general population. Despite major advances in medicine, most diseases today are still identified only after symptoms appear — often limiting opportunities for earlier intervention and prevention. While genomic sequencing has generated vast amounts of biological data, one of healthcare's biggest challenges has been translating that data into actionable health insights at scale. Human Longevity's new offering honors the legacy of Dr. J. Craig Venter, whose pioneering work helped decode the first human genome and transform modern medicine. More than two decades ago, the Human Genome Project required over $3 billion and years of international effort to decode a single human genome. Today, Human Longevity is making a clinical grade genome sequencing broadly accessible with a comprehensive AI-enhanced genomic insight platform for just $599. Dr. Venter long predicted that the human genome would play an increasingly important role in managing individual health and preventing disease. In recent years, a growing body of global scientific research has continued to validate this vision, demonstrating that genomics is becoming a foundational tool for predicting disease risk, guiding prevention strategies, and enabling more personalized healthcare. "Dr. Venter believed that genomics would fundamentally transform medicine from reactive sick care to a proactive healthcare model," said Wei-Wu He, Ph.D. Executive Chairman of Human Longevity Inc. "A decade ago, he founded Human Longevity to combine whole genome sequencing with advanced imaging, including Whole Body MRI, multi-omics data, longitudinal health data and AI, to help people live longer, healthier lives. We are proud to continue that mission by democratizing access to decades of work led by Human Longevity." Over the last decade, Human Longevity has invested more than $600 million building one of the world's most comprehensive longitudinal health datasets. The company has collected and analyzed data from more than 10,000 individuals over a 10-year period, enabling the development of proprietary AI-driven insights focused on major age-related chronic diseases such as cardiovascular disease, cancer, and dementia. The new Clinical-Grade Whole Genome Sequencing Insight Report is designed to provide individuals with actionable insights into inherited disease risks, carrier status, pharmacogenomics, longevity-associated traits, and personalized disease prevention opportunities. "Our vision is simple," added Dr. He. "Every individual should have access to their genome and AI-powered health insights. The genome is the foundation of modern preventive medicine." The new service will be available nationwide immediately through Human Longevity's website. For more information, visit: Human Longevity Website About Human Longevity, Inc. Founded in 2013, Human Longevity, Inc. is a biotechnology company at the forefront of integrating genomics, artificial intelligence, and multimodal diagnostics to extend human healthspan founded by genomics pioneer J. Craig Venter. HLI delivers comprehensive, data-driven evaluations designed to identify and mitigate disease risk long before symptoms arise. The company is committed to redefining healthcare through AI-driven proactive diagnostics and personalized preventive care. To learn more, visit . Media Contact: [email protected] SOURCE Human Longevity, Inc. 21% more press release views with Request a Demo